JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

NVS

149.86

+0.11%↑

Kodu・Aktsiate loetelu・Eli Lilly and Co.

Eli Lilly and Co.

Suletud

SektorTervishoid

1,007.5 -0.79

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

995

Max

1015.5

Põhinäitajad
By Trading Economics
Sissetulek	758M 7.4B
Müük	507M 20B
P/E Sektori keskmine	34.327 51.415
Aktsiakasum	8.55
Dividenditootlus	0.66
Kasumimarginaal	37.355
Töötajad	50,000
EBITDA	971M 9.4B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.33% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.66% 2.34%
Järgmine tulemuste avaldamine	5. aug 2026
Järgmine dividendimakse kuupäev	10. juuni 2026
Järgmine aktsia dividendi kuupäev (ex-date)	15. mai 2026

Turustatistika
By TradingEconomics
Turukapital	87B 862B
Eelmine avamishind	1008.29
Eelmine sulgemishind	1007.5

Uudiste sentiment

By Acuity

33%

67%

93 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 884.54 Toetus ja vastupanu

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 12:01 UTC

Tulu

Suurimad hinnamuutused turgudel

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

7. mai 2026, 09:30 UTC

Tulu

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6. mai 2026, 12:36 UTC

Tulu

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6. mai 2026, 10:12 UTC

Tulu

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6. mai 2026, 09:58 UTC

Tulu

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30. apr 2026, 20:59 UTC

Kuumad aktsiad

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30. apr 2026, 20:12 UTC

Tulu

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30. apr 2026, 16:43 UTC

Tulu

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30. apr 2026, 16:10 UTC

Market Talk

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30. apr 2026, 15:13 UTC

Tulu

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30. apr 2026, 14:58 UTC

Tulu

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30. apr 2026, 14:53 UTC

Tulu

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30. apr 2026, 14:50 UTC

Tulu

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30. apr 2026, 14:42 UTC

Tulu

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30. apr 2026, 14:39 UTC

Tulu

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30. apr 2026, 14:35 UTC

Tulu

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30. apr 2026, 14:24 UTC

Tulu

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30. apr 2026, 14:17 UTC

Tulu

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30. apr 2026, 13:56 UTC

Tulu

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30. apr 2026, 13:37 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30. apr 2026, 12:32 UTC

Market Talk

Tulu

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30. apr 2026, 12:29 UTC

Market Talk

Tulu

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30. apr 2026, 12:23 UTC

Market Talk

Tulu

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30. apr 2026, 12:10 UTC

Tulu

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30. apr 2026, 12:08 UTC

Tulu

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30. apr 2026, 12:04 UTC

Market Talk

Tulu

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30. apr 2026, 11:39 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30. apr 2026, 11:08 UTC

Tulu

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30. apr 2026, 10:50 UTC

Tulu

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30. apr 2026, 10:49 UTC

Tulu

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

24.33% tõus

12 kuu keskmine prognoos

Keskmine 1,262.85 USD 24.33%

Kõrge 1,500 USD

Madal 850 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Eli Lilly and Co. aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 884.54Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

93 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.